0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Chronic Myelocytic Leukemia (CML) -Epidemiology Forecast to 2028
Published Date: March 2019
|
Report Code: DELV-Epid-319
Home | Market Reports | Health | Health Conditions | Cancer
Chronic Myelocytic Leukemia Epidemiology Forecast to 2028

Chronic Myelocytic Leukemia (CML) -Epidemiology Forecast to 2028

Code: DELV-Epid-319
Report
March 2019
50 Pages
Delveinsight
Region: Global,
Description
Table of Content
Tables & Figures

DelveInsight's "Chronic Myelocytic Leukemia (CML)  - Epidemiology Forecast, 2028” report provides a comprehensive analysis of the Chronic Myelocytic Leukemia (CML)  epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2028.

Markets Covered
• United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

 Study Period: 2016-2028

Chronic Myelocytic Leukemia (CML)  Epidemiology
The epidemiology section covers the historical, current as well as forecasted epidemiology for Chronic Myelocytic Leukemia (CML)  in 7 major markets. The data is collected by understanding the disease, reviewing numerous studies conducted by countries and by exploring different surveys as well as reports. The Key opinion leaders’ views are also taken into account to provide a deep understanding of the Chronic Myelocytic Leukemia (CML)  outlook. It also includes the explanation of changing trends of epidemiology outlining the Chronic Myelocytic Leukemia (CML)  scenario.

Chronic Myelocytic Leukemia (CML)  Epidemiology Segmentation
The epidemiology section is further segmented according to the patient pool characteristics, such as age-specific, type-specific, sub-type specific, gender-specific etc., thus providing an in-depth and high-quality analysis. The report also covers the prevalent/Incidence cases as well as the treatable cases as per the therapies available for the Chronic Myelocytic Leukemia (CML)  thereby presenting the trends with detailed analysis, with the assumptions undertaken. The data is presented in the form of graphs along with tables to effectively summarize the landscape.

Report Scope
• The report covers detailed overview of Chronic Myelocytic Leukemia (CML)  explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• It provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
• The Chronic Myelocytic Leukemia (CML)  Report assesses the disease risk and burden and highlights the unmet needs
• It also helps to recognize the growth opportunities in the 7MM with respect to the patient population

Key strengths
• 10 Year Forecast
• 7MM Coverage
• Total Cases in Chronic Myelocytic Leukemia (CML)

Key assessments
• Patient Segmentation in Chronic Myelocytic Leukemia (CML)
• Chronic Myelocytic Leukemia (CML)  Risk & Burden
• Factors driving growth in a specific Chronic Myelocytic Leukemia (CML)  patient population

1.Report Introduction
2. Chronic Myelocytic Leukemia (CML) Epidemiology Overview at a Glance
2.1. Patient Share Distribution of Chronic Myelocytic Leukemia (CML) in 2016
2.2. Patient Share Distribution of Chronic Myelocytic Leukemia (CML) in 2028
3. Disease Background and Overview: Chronic Myelocytic Leukemia (CML)
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Chronic Myelocytic Leukemia (CML) in 7MM
4.3. Total Prevalent/ Incident Patient Population of Chronic Myelocytic Leukemia (CML) in 7MM – By Countries
5. Epidemiology of Chronic Myelocytic Leukemia (CML) by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML)
5.1.3. Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML) *
5.1.4. Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML)*
5.1.5. Diagnosed Cases of the Chronic Myelocytic Leukemia (CML)
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML)
5.4.3. Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML)*
5.4.4. Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML)*
5.4.5. Diagnosed Cases of the Chronic Myelocytic Leukemia (CML)
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML)
5.5.3. Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML)*
5.5.4. Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML)*
5.5.5. Diagnosed Cases of the Chronic Myelocytic Leukemia (CML)
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML)
5.6.3. Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML)*
5.6.4. Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML)*
5.6.5. Diagnosed Cases of the Chronic Myelocytic Leukemia (CML)
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML)
5.7.3. Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML)*
5.7.4. Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML)*
5.7.5. Diagnosed Cases of the Chronic Myelocytic Leukemia (CML)
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML)
5.8.3. Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML)*
5.8.4. Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML)*
5.8.5. Diagnosed Cases of the Chronic Myelocytic Leukemia (CML)
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML)
5.9.3. Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML)*
5.9.4. Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML)*
5.9.5. Diagnosed Cases of the Chronic Myelocytic Leukemia (CML)
6. Unmet Needs of the Chronic Myelocytic Leukemia (CML)
7. Appendix
8. Report Methodology
8.1. Sources
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight
*Indication Specific

List of Table:

Table 1: Total Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in 7MM
Table 2: Total Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML) in United States (2016-2028)*
Table 5: Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML) in United States (2016-2028)*
Table 6: Diagnosed Cases of the Chronic Myelocytic Leukemia (CML) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML) in Germany (2016-2028) *
Table 9: Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML) in Germany (2016-2028) *
Table 10: Diagnosed Cases of the Chronic Myelocytic Leukemia (CML) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML) in France (2016-2028) *
Table 13: Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML) in France (2016-2028) *
Table 14: Diagnosed Cases of the Chronic Myelocytic Leukemia (CML) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML) in Italy (2016-2028) *
Table 17: Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML) in Italy (2016-2028) *
Table 18: Diagnosed Cases of the Chronic Myelocytic Leukemia (CML) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML) in Spain (2016-2028) *
Table 21: Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML) in Spain (2016-2028) *
Table 22: Diagnosed Cases of the Chronic Myelocytic Leukemia (CML) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML) in UK (2016-2028) *
Table 25: Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML) in UK (2016-2028) *
Table 26: Diagnosed Cases of the Chronic Myelocytic Leukemia (CML) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML) in Japan (2016-2028) *
Table 29: Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML) in Japan (2016-2028) *
Table 30: Diagnosed Cases of the Chronic Myelocytic Leukemia (CML) in Japan (2016-2028)

List of Figure:

Figure 1: Total Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML) in United States (2016-2028)*
Figure 5: Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML) in United States (2016-2028)*
Figure 6: Diagnosed Cases of the Chronic Myelocytic Leukemia (CML) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML) in Germany (2016-2028) *
Figure 9: Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML) in Germany (2016-2028) *
Figure 10: Diagnosed Cases of the Chronic Myelocytic Leukemia (CML) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML) in France (2016-2028) *
Figure 13: Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML) in France (2016-2028) *
Figure 14: Diagnosed Cases of the Chronic Myelocytic Leukemia (CML) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML) in Italy (2016-2028) *
Figure 17: Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML) in Italy (2016-2028) *
Figure 18: Diagnosed Cases of the Chronic Myelocytic Leukemia (CML) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML) in Spain (2016-2028) *
Figure 21: Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML) in Spain (2016-2028) *
Figure 22: Diagnosed Cases of the Chronic Myelocytic Leukemia (CML) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML) in UK (2016-2028) *
Figure 25: Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML) in UK (2016-2028) *
Figure 26: Diagnosed Cases of the Chronic Myelocytic Leukemia (CML) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML) in Japan (2016-2028) *
Figure 29: Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML) in Japan (2016-2028) *
Figure 30: Diagnosed Cases of the Chronic Myelocytic Leukemia (CML) in Japan (2016-2028)

 

SELECT A FORMAT
Added to Cart

Electronic (PDF)
$3250
This license allows only one user to access the PDF.

Electronic (PDF)
$6500
This license allows all the users of an enterprise residing in one location to access the PDF

Electronic (PDF)
$9750
This license allows all the employees of an enterprise to access the PDF.
Add to Cart
Buy Now (10% Discount)
OUR CUSTOMER
Nano Dimension

RELATED REPORTS

Global Nimotuzumab Market Insights and Forecast to 2028
Global Nimotuzumab Market Insights and Forecast to 2028

120 Pages
Type: Report
Code: QYRE-Auto-32F7763
Tue May 03 00:00:00 UTC 2022

Add to Cart

Global Nivolumab Injection Market Insights and Forecast to 2028
Global Nivolumab Injection Market Insights and Forecast to 2028

120 Pages
Type: Report
Code: QYRE-Auto-27N7625
Tue May 03 00:00:00 UTC 2022

Add to Cart

Global Antineoplastic Agents Market Insights and Forecast to 2028
Global Antineoplastic Agents Market Insights and Forecast to 2028

As for the Europe Antineoplastic Agents landscape Germany is projected to reach US million by 2028 trailing a CAGR of over the forecast period.Global Antineoplastic Agents Market Insights and Forecast to 2028.

120 Pages
Type: Report
Code: QYRE-Auto-23H9930
Tue May 03 00:00:00 UTC 2022

Add to Cart

Global Doxifluridine Market Insights and Forecast to 2028
Global Doxifluridine Market Insights and Forecast to 2028

120 Pages
Type: Report
Code: QYRE-Auto-17U5994
Tue May 03 00:00:00 UTC 2022

Add to Cart